Last checked at 29 May 2018 13:21
Oxford BioMedica plc
Result of General Meeting
London, UK - 29 May 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group announces, in accordance with Listing Rule 9.6.18R, that the ordinary resolution (the "Resolution") proposed at its General Meeting held today in London providing the requisite approvals and authorities from the shareholders of Oxford BioMedica in relation to the share capital consolidation (the "Consolidation"), as set out in the notice of general meeting contained in the circular sent to shareholders on 4 May 2018 (the "Circular"), was duly passed.
The full text of the Resolution can be viewed in the notice of general meeting contained in the Circular by visiting the Group's website at www.oxfordbiomedica.co.uk.
In accordance with Listing Rule 9.6.2R a copy of the Resolution has been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (24 May 2018) there were 3,285,053,283 1p ordinary shares in issue, each carrying one vote per share.
Resolution |
Votes For | Votes at Chairman's Discretion | Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast | Result |
Ordinary resolution | |||||||
1 | 1,438,538,054 | 1,778,687 | 5,741,189 | 1,219,914 | 549,974,478 | 1,997,252,322 | Passed |
The Consolidation
The Consolidation will replace every 50 Existing Ordinary Shares of 1 pence each with 1 New Consolidated Ordinary Share of 50 pence each and will take effect at 8:00 a.m. on 30 May 2018, conditional upon admission of the New Consolidated Ordinary Shares to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange becoming effective.
Following the Consolidation the total issued share capital of Oxford BioMedica will be 65,701,066 New Consolidated Ordinary Shares of 50 pence each.
- Ends -
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer
|
Tel: +44 (0)1865 783 000 |
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
|
Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.